EKF Diagnostics (LON:EKF) Stock Crosses Above 200 Day Moving Average - Should You Sell?

EKF Diagnostics Holdings plc (LON:EKF - Get Free Report)'s stock price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 23.83 ($0.32) and traded as high as GBX 25.90 ($0.35). EKF Diagnostics shares last traded at GBX 25.90 ($0.35), with a volume of 20,041 shares.

EKF Diagnostics Stock Down 2.3%

The stock's fifty day moving average is GBX 23.47 and its two-hundred day moving average is GBX 23.83. The company has a current ratio of 4.60, a quick ratio of 1.77 and a debt-to-equity ratio of 0.34. The company has a market capitalization of £115.12 million, a PE ratio of 24.10 and a beta of 0.57.

EKF Diagnostics (LON:EKF - Get Free Report) last issued its quarterly earnings results on Tuesday, March 25th. The company reported GBX 1.38 ($0.02) earnings per share for the quarter. EKF Diagnostics had a net margin of 9.37% and a return on equity of 7.03%. As a group, analysts predict that EKF Diagnostics Holdings plc will post 2.2987842 EPS for the current year.

Insider Buying and Selling

In other EKF Diagnostics news, insider Gavin T. Jones acquired 50,000 shares of the company's stock in a transaction on Tuesday, March 25th. The shares were acquired at an average cost of GBX 22 ($0.30) per share, with a total value of £11,000 ($14,767.08). 5.24% of the stock is owned by insiders.

EKF Diagnostics Company Profile

EKF is an AIM-listed global diagnostics business focussed on: ● Point-of-Care analysers in the key areas of Hematology and Diabetes ● Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications. EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.